FDA Won't Take Action on Compounding Versions of KV Pharma's (KV.A) Makena; Shares Sink
Tweet
Share
E-mail
FDA releases on statement on KV Pharma's (NYSE: KV.A) (NYSE: KV-A) Makena, saying that the agency won't take action on compounding pharmacies which make version of hydroxyprogesterone caproate, an active ingredient in the KV drug.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech ends colorectal cancer mRNA therapy trial early
- FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
- FDA clears Lilly's Mounjaro for cardiovascular risk in type 2 diabetes
Create E-mail Alert Related Categories
FDA, Hot FDA News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
